| Literature DB >> 23621810 |
Alexander D Liddle1, Keshtra Satchithananda, Johann Henckel, Shiraz A Sabah, Karuniyan V Vipulendran, Angus Lewis, John A Skinner, Adam W M Mitchell, Alister J Hart.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2013 PMID: 23621810 PMCID: PMC3715818 DOI: 10.3109/17453674.2013.797313
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Preoperative and demographic details
| No. | Age | Sex | Prosthesis | Modular | Head | Cup | Incl. | Ver. | Survival (m) | Co | Cr |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 50 | F | BHR | Resurfacing | 50 | 56 | 71 | 42 | 31 | 47 | 33 |
| 2 | 55 | M | BHR | Resurfacing | 46 | 54 | 29 | -34 | 13 | 0.9 | 1.5 |
| 3 | 63 | F | ASR | Resurfacing | 47 | 54 | 55 | 48 | 29 | 30 | 32 |
| 4 | 65 | F | ASR | Resurfacing | 40 | 48 | 66 | 28 | 53 | 24 | 21 |
| 5 | 72 | F | BHR | Resurfacing | 50 | 56 | 44 | 29 | 59 | 3.1 | 2.3 |
| 6 | 65 | F | BHR | Resurfacing | 42 | 48 | 38 | 9 | 61 | 1.1 | 1.3 |
| 7 | 69 | F | BHR | Resurfacing | 42 | 48 | 56 | 23 | 82 | 1.7 | 2.7 |
| 8 | 63 | F | BHR | Resurfacing | 42 | 50 | 40 | 7 | 95 | 7.7 | 9.4 |
| 9 | 46 | F | Cormet | Resurfacing | 44 | 50 | 75 | 34 | 18 | 3.3 | 0.3 |
| 10 | 65 | F | BHR | Resurfacing | 42 | 50 | 57 | 26 | 56 | 21 | 11 |
| 11 | 66 | M | Cormet | Resurfacing | 48 | 54 | 60 | 29 | 68 | 12 | 6.0 |
| 12 | 74 | F | BHR | Resurfacing | 44 | 50 | 34 | 32 | 54 | 1.5 | 1.0 |
| 13 | 48 | F | BHR | Resurfacing | 46 | 54 | 41 | 27 | 45 | 1.8 | 6.7 |
| 14 | 48 | F | BHR | Resurfacing | 48 | 54 | 47 | 26 | 52 | 1.8 | 6.7 |
| 15 | 73 | F | Durom | THA | 50 | 56 | 55 | 37 | 38 | 6.5 | 8.4 |
| 16 | 35 | F | Cormet | Resurfacing | 44 | 50 | 43 | 26 | 11 | 1.6 | 8.6 |
| 17 | 57 | F | ASR | Resurfacing | 53 | 60 | 70 | 43 | 45 | 165 | 117 |
| 18 | 60 | M | BHR | Resurfacing | 50 | 56 | 51 | 12 | 43 | 1.0 | 2.7 |
| 19 | 67 | M | Mitch | THA | 44 | 50 | 60 | -6 | 13 | 1.2 | 0.5 |
| 20 | 64 | M | BHR | Resurfacing | 50 | 56 | 57 | 43 | 92 | 71 | 36 |
| 21 | 67 | F | Biomet | Resurfacing | 44 | 50 | 49 | 9 | 28 | 9.5 | 1.0 |
| 22 | 67 | F | Biomet | Resurfacing | 44 | 50 | 38 | -5 | 22 | 9.5 | 1.0 |
| 23 | 61 | F | BHR | Resurfacing | 42 | 50 | 64 | 13 | 43 | 2.1 | 3.1 |
| 24 | 47 | F | BHR | Resurfacing | 42 | 50 | 43 | 39 | 65 | 0.5 | 0.7 |
| 25 | 74 | F | BHR | THA | 50 | 56 | 37 | 19 | 49 | 8.8 | 3.0 |
| 26 | 69 | M | BHR | Resurfacing | 54 | 60 | 73 | 41 | 63 | 33 | 14 |
| 27 | 60 | F | BHR | Resurfacing | 46 | 52 | 36 | 26 | 68 | 1.5 | 3.5 |
| 28 | 25 | F | Cormet | Resurfacing | 40 | 48 | 47 | 45 | 39 | 70 | 32 |
| 29 | 61 | F | Pinnacle | THA | 36 | 52 | 68 | -3 | 56 | 102 | 37 |
| 30 | 55 | F | BHR | Resurfacing | 46 | 50 | 64 | 30 | 72 | 98 | 49 |
| 31 | 69 | F | ASR | Resurfacing | 43 | 48 | 55 | 27 | 62 | 11 | 6.6 |
| 32 | 45 | F | ASR | THA | 45 | 50 | 57 | 35 | 38 | 10 | 3.5 |
| 33 | 46 | F | ASR | THA | 45 | 50 | 47 | 10 | 3.5 | ||
| 34 | 66 | F | BHR | Resurfacing | 42 | 50 | 66 | 34 | 68 | 105 | 52 |
| 35 | 61 | M | BHR | Resurfacing | 46 | 52 | 43 | 22 | 131 | 3.8 | 2.9 |
| 36 | 31 | F | Cormet | Resurfacing | 40 | 46 | 42 | 24 | 30 | 20 | 6.8 |
| 37 | 58 | F | BHR | Resurfacing | 46 | 52 | 42 | 20 | 25 | 3.1 | 4.8 |
| 38 | 44 | F | Mitch | Resurfacing | 52 | 58 | 38 | 38 | 21 | 23 | 13 |
| 39 | 72 | F | Taperloc Magnum | THA | 44 | 50 | 28 | 9.4 | 0.5 |
Incl. and Ver.: inclination and version measured by CT (radiographic values);
Co and Cr: whole-blood cobalt and chromium (parts per billion);
BHR: Birmingham Hip Resurfacing (Smith and Nephew);
ASR: Anatomical Surface Replacement (DePuy Johnson and Johnson).
Figure 5.Case 32 with destructive solid pseudotumor.
Figure 4.Preoperative radiograph of patient 34 demonstrating extensive osteolysis adjacent to the right acetabular component.
Outcomes
| Type | Description | n | Preoperative OHS median (range) | Postoperative OHS median (range) | ΔOHS (range) | p-value |
|---|---|---|---|---|---|---|
| Whole cohort | 39 | 15 (2–31) | 36.5 (9–48) | 17 (–10 to 41) | < 0.001 | |
| Subgroup | ||||||
| 1 | Conventional | 8 | 17 (2–30) | 32 (20–46) | 17 (–10 to 41) | 0.08 |
| 2 | Synovitis | 14 | 11 (4–29) | 33 (9–44) | 14 (4–33) | 0.002 |
| 3 | Soft tissue disruption | 6 | 27 (14–31) | 47 (29–48) | 16 (6–33) | 0.04 |
| 4 | Bone destruction | 7 | 20 (10–28) | 41 (39–45) | 22 (12–35) | 0.03 |
| 5 | Solid pseudotumor | 4 | 8 (2–22) | 29.5 (15–31) | 16.5 (9–23) | 0.07 |
Types of failure
| Imaging | Surgical | Hazards | Surgical plan | |
|---|---|---|---|---|
| Type I: | ||||
| Conventional failure modes | Normal or small fluid-filled ‘pseudotumor’ on MRI | Variable | Misdiagnosis, Recurrent infection | |
| Type II: | ||||
| Synovitis with negative investigations | Normal or small fluid-filled ‘pseudotumor’ on MRI | Varying degrees of synovitis | Misdiagnosis | Need to exclude other causes e.g. infection, mechanical causes. Consider further imaging for psoas, frozen section during revision |
| Type III: | ||||
| Soft tissue disruption | MRI shows fluid or solid mass with variable soft tissue and muscle destruction ( | Abductors may be atrophic or avulsed/absent | Instability after revision | Plan for possibility of muscle loss, including need for musle reconstruction (e.g. graft jacket) or captive cup. Like type V, may need pelvic surgeon for full excision of intrapelvic mass |
| Type IV: | ||||
| Bone destruction | Osteolysis on CT/plain films. MRI as type I ( | Loose cup. Soft tissue reaction varies | Loss of bone stock and need for extensive reconstruction | May need extensive reconstruction. CT and pelvic surgeon may be helpful. Early surgery indicated to prevent fracture |
| Type V: | ||||
| Solid pseudotumor | MRI shows large mass. Mass may extend to pelvis ( | Massive soft tissue reaction but musculature may be intact | Secondary infection if incompletely excised | Complete excision required. May need pelvic exploration |
MRI and intraoperative appearances; revision surgery performed
| Hip | MRI mass and class | MRI muscle destruction | Intraoperative appearance | Type | Revision prosthesis and bearing | |
|---|---|---|---|---|---|---|
| No. | Abductor | SER | ||||
| 1 | N/A | N/A | N/A | Synovitis, no mass | II | COC |
| 2 | Nil | Moderate | Severe | Clear impingement, no mass | I | COC |
| 3 | Nil | Moderate | Severe | Synovitis, no mass | II | COC |
| 4 | Nil | Moderate | Severe | Synovitis, no mass | II | COC |
| 5 | Nil | Moderate | Severe | Osteolysis, acetabular # 2º to minor trauma, no mass | III | COC |
| 6 | Nil | Mild | None | Synovitis, no mass | II | MOM |
| 7 | N/A | N/A | N/A | Mass, abductors preserved | III | COC |
| 8 | 2a | None | Mild | Synovitis, no mass | II | COC |
| 9 | 3 | Moderate | Severe | Solid mass, pelvic extension, abductors preserved | V | Revision stem COC |
| 10 | 2a | Moderate | Moderate | Loose femoral component with osteolysis | IV | COC |
| 11 | N/A | N/A | N/A | Synovitis and acetabular loosening. Infection confirmed on histology/microbiology | I | COC |
| 12 | N/A | N/A | N/A | Femoral neck fracture, no mass | I | MOM |
| 13 | 1 | Mild | Moderate | Synovitis, no mass | II | COC |
| 14 | 2a | Mild | Moderate | Synovitis, no mass | II | COC |
| 15 | Nil | None | Severe | Impingement, no mass | I | COC |
| 16 | Nil | None | None | Synovitis, no mass | II | COC |
| 17 | 2a | Severe | Moderate | Mass, gluteal dehiscence, bare trochanter | III | COC |
| 18 | Nil | Mild | Moderate | Synovitis, no mass | II | COC |
| 19 | Nil | Moderate | Moderate | Synovitis, no mass | I | COC |
| 20 | 2a | Mild | Mild | Massive pelvic osteolysis | IV | Pelvic recon, COC |
| 21 | 2a | Mild | Moderate | No mass, osteolysis with loose cup | IV | COC |
| 22 | 2a | Mild | Severe | No mass, osteolysis with loose cup | IV | COC |
| 23 | Nil | Moderate | Severe | Loose – loss of fixation with BHR dysplasia cup | I | COC |
| 24 | Nil | Moderate | Moderate | Synovitis, no mass | II | COC |
| 25 | 2a | Severe | Moderate | Complete destruction of SERs, bone death at GT | III | Revision stem, MOP |
| 26 | 2b | Moderate | Mild | Pelvic osteolysis, no mass | IV | MOP |
| 27 | Nil | Mild | Severe | Synovitis, no mass | II | MOP |
| 28 | Nil | Nil | Nil | Synovitis, no mass | II | MOP |
| 29 | 2a | Severe | Moderate | Severe synovitis. No mass | II | MOP |
| 30 | 2a | Moderate | Moderate | Very large fluid-filled mass, no muscle dehiscence but atrophic | III | MOP |
| 31 | Nil | None | Moderate | Synovitis, no mass | II | MOP |
| 32 | 3 | Moderate | Moderate | Solid mass with massive muscle destruction bilaterally | V | Captive cup, MOP |
| 33 | 3 | Moderate | Moderate | Same patient as above | V | Captive cup, MOP |
| 34 | 3 | Mild | Severe | Pelvic osteolysis, no mass | IV | TMT cup, COC |
| 35 | Nil | Mild | Moderate | Pelvic osteolysis, no mass | IV | MOP |
| 36 | 2a | None | Moderate | Infected. No mass | I | COC |
| 37 | 1 | Moderate | Severe | Complete destruction of SERs with mass | III | COC |
| 38 | 2b | Moderate | Severe | Infected | I | COC |
| 39 | 3 | Severe | Severe | Solid mass with widespread destruction. Symptomatic encasement of sciatic nerve | V | COC |
COC = ceramic-on-ceramic; MOM = metal-on-metal;
MOP = metal-on-polyethylene; SER = short external rotators